H. Lundbeck A/S

CPSE:HLUN B Voorraadrapport

Marktkapitalisatie: DKK 43.3b

H. Lundbeck Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van H. Lundbeck zullen naar verwachting dalen met respectievelijk 3.3% en 6.2% per jaar. De winst per aandeel zal naar verwachting afnemen met 5.3% per jaar. Het rendement op het eigen vermogen zal naar verwachting 12.1% in 3 jaar.

Belangrijke informatie

-6.2%

Groei van de winst

-5.27%

Groei van de winst per aandeel

Pharmaceuticals winstgroei12.3%
Inkomstengroei-3.3%
Toekomstig rendement op eigen vermogen12.12%
Dekking van analisten

Good

Laatst bijgewerkt09 Sep 2026

Recente toekomstige groei-updates

Analyse-artikel • Aug 22

H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

A week ago, H. Lundbeck A/S ( CPH:HLUN B ) came out with a strong set of second-quarter numbers that could potentially...
Analyse-artikel • May 15

Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Analyse-artikel • Feb 07

H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...
Analyse-artikel • Nov 15

Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...

Recent updates

Narratiefupdate • Aug 23

HLUN B: Advancing Neuroscience Pipeline Will Support Future Upside Potential

Analysts have raised their fair value estimate for H. Lundbeck from DKK 47.21 to DKK 48.73.
Analyse-artikel • Aug 22

H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

A week ago, H. Lundbeck A/S ( CPH:HLUN B ) came out with a strong set of second-quarter numbers that could potentially...
Narratiefupdate • Jun 22

HLUN B: Neuroscience Pipeline Progress Will Support Future Upside Potential

Analysts have maintained their fair value estimate for H. Lundbeck at DKK 47.21.
Analyse-artikel • Jun 18

H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data

H. Lundbeck (CPSE:HLUN B) stock is in focus after the company reported preliminary Phase II Part A data for asedebart in Cushing's disease, showing urinary free cortisol normalization in most evaluable patients. See our latest analysis for H. Lundbeck. The preliminary asedebart data arrives after a steady run in H. Lundbeck's stock, with the latest share price at DKK42.32, a 30 day share price return of 5.43% and a 90 day share price return of 13.95%, while the 1 year total shareholder return...
Narratiefupdate • Jun 06

HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple

Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.
Analyse-artikel • May 24

H. Lundbeck's (CPH:HLUN B) Solid Earnings Have Been Accounted For Conservatively

H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...
Narratiefupdate • May 23

HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside

Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.
Analyse-artikel • May 15

Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Narratiefupdate • May 05

HLUN B: Late-Stage Neurology Pipeline Will Support Future Margins

Analysts have nudged their fair value estimate for H. Lundbeck stock from DKK 61.99 to DKK 63.32, reflecting updated views on revenue growth, profit margins and future P/E assumptions.
Narratiefupdate • Apr 20

HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook

Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.
Narratiefupdate • Apr 05

HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins

Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.
Narratiefupdate • Mar 22

HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion

Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.
Narratiefupdate • Mar 08

HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential

Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.
Narratiefupdate • Feb 22

HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook

Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.
Narratiefupdate • Feb 08

HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares

Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.
Analyse-artikel • Feb 07

H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...
Narratiefupdate • Jan 25

HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook

Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.
Analyse-artikel • Jan 14

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Narratiefupdate • Jan 11

HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook

Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.
Narratiefupdate • Dec 27

HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements

Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.
Narratiefupdate • Dec 13

HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares

Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.
Analyse-artikel • Nov 22

The Strong Earnings Posted By H. Lundbeck (CPH:HLUN B) Are A Good Indication Of The Strength Of The Business

H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...
Analyse-artikel • Nov 15

Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...
Analyse-artikel • Oct 28

Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)

With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...
Narratiefupdate • Sep 05

CNS Pipeline And Global Expansion Will Unlock Future Opportunities

With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.

Winst- en omzetgroeiprognoses

CPSE:HLUN B - Toekomstschattingen van analisten en financiële gegevens uit het verleden (DKK Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202825,3534,3595,5866,26711
12/31/202726,0324,6576,0726,90612
12/31/202625,9084,5816,0086,83311
6/30/202625,9603,9355,1565,797N/A
3/31/202625,5203,7304,8255,448N/A
12/31/202524,6303,1924,8635,481N/A
9/30/202524,0783,7542,7783,406N/A
6/30/202523,5213,4302,8513,409N/A
3/31/202522,9513,2572,4152,997N/A
12/31/202422,0043,1432,7613,326N/A
9/30/202421,4412,6874,9365,421N/A
6/30/202420,6712,5864,1284,609N/A
3/31/202420,1562,4164,1454,663N/A
12/31/202319,9122,2903,5794,080N/A
9/30/202319,6142,4673,5284,426N/A
6/30/202319,3812,4793,5234,457N/A
3/31/202318,9182,3843,2924,102N/A
12/31/202218,2461,9162,6993,519N/A
9/30/202217,6191,6032,0512,615N/A
6/30/202216,9131,2361,7442,313N/A
3/31/202216,3981,1091,3441,959N/A
12/31/202116,2991,3181,6602,272N/A
9/30/202116,5211,8732,4052,949N/A
6/30/202116,9711,9652,3792,912N/A
3/31/202117,3812,1103,2633,757N/A
12/31/202017,6721,5813,3593,837N/A
9/30/202017,8189042,7133,171N/A
6/30/202017,4901,2422,9103,354N/A
3/31/202017,3661,507N/A1,960N/A
12/31/201917,0362,313N/A2,609N/A
9/30/201916,8113,091N/A3,621N/A
6/30/201917,3093,395N/A3,462N/A
3/31/201917,7663,606N/A4,815N/A
12/31/201818,1173,907N/A5,981N/A
9/30/201818,3133,806N/A5,922N/A
6/30/201818,0283,627N/A6,197N/A
3/31/201817,6083,236N/A5,397N/A
12/31/201717,2342,624N/A4,045N/A
9/30/201717,0072,544N/A3,731N/A
6/30/201716,6071,988N/A3,551N/A
3/31/201716,0751,612N/A3,420N/A
12/31/201615,6341,211N/A3,126N/A
9/30/201615,202290N/A4,158N/A
6/30/201614,923-1,289N/A2,755N/A
3/31/201614,801-5,427N/A936N/A
12/31/201514,594-5,694N/A197N/A
9/30/201514,108-5,879N/A-1,330N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van HLUN B zal naar verwachting de komende 3 jaar dalen ( -6.2% per jaar).

Winst versus markt: De winst van HLUN B zal naar verwachting de komende 3 jaar dalen ( -6.2% per jaar).

Hoge groeiwinsten: De winst van HLUN B zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van HLUN B zal naar verwachting de komende 3 jaar dalen ( -3.3% per jaar).

Hoge groei-inkomsten: De omzet van HLUN B zal naar verwachting de komende 3 jaar dalen ( -3.3% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen HLUN B zal naar verwachting over 3 jaar laag zijn ( 12.1 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/09/09 13:15
Aandelenkoers aan het einde van de dag2026/09/09 00:00
Inkomsten2026/06/30
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

H. Lundbeck A/S wordt gevolgd door 34 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Rosie TurnerBarclays
Charles PitmanBarclays
Emily FieldBarclays